DOVATO is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.[3]

Treat Ahead with DOVATO  Your DOVATO patients

Treat Ahead from the start with DOVATO[1–3]

~150 people every hour were newly diagnosed with HIV globally in 2024.[4] With proven efficacy in newly diagnosed people living with HIV and fewer medicines vs. 3DRs, DOVATO can help you support your patients' long-term health from diagnosis and in the future.[1–3,5,6]

Proven efficacy

Rapid[2,7]
Robust[1,2,8,9]
Durable[2]

Proven viral suppression in people naïve to treatment living with HIV[1,2,8,9]

Explore efficacy of DOVATO

High barrier to resistance

Proven high barrier to resistance[1–3]

Demonstrated across 5 RCTs and a systematic literature review of real-world evidence[1,2,5,8,9]

Discover barrier to resistance

Fewer medicines vs. 3-drug regimens.

The confidence of guideline
recommendations

The BHIVA guidelines and 4 international guidelines (DHHS, EACS, IAS, WHO) recommend DOVATO for newly diagnosed people living with HIV[10–14]

Find out ‘why DOVATO?’

Support your naïve to treatment patients now and for the future[1,2,8,9]

People living with HIV are living longer than ever before.[15] That is why it is important to recognise and consider the challenges that may impact them now and in the future.[1,2,8,9]

Lethabo

Lethabo
39 years old

Presenting with a high viral load and unknown baseline resistance

Review efficacy data

Michael

Michael
25 years old

Diagnosed with a very high viral load in a test-and-treat setting

See rapid ART initiation

Donna

Donna
55 years old

Presenting with a high viral load and hypertension

Explore DDI profile

Carlos

Carlos
48 years old

Presenting with low CD4+ T-cell count and additional health concerns

Find out 'why DOVATO'?

Proven Efficacy.[1–3]
High Barrier to Resistance.[1–3]
Fewer medicines vs. 3-drug regimens.[3]

3DR, 3-drug regimen; AIDS, acquired immunodeficiency syndrome; ART, antiretroviral therapy; BHIVA, British HIV Association; DDI, drug-drug interaction; DHHS, Department of Health and Human Services; EACS, European AIDS Clinical Society; IAS, International Antiviral Society; RCT, randomised controlled trial; WHO, World Health Organization.

References:

  1. Figueroa M et al. Clin Infect Dis 2025. https://doi.org/10.1093/cid/ciaf415. [Epub ahead of print].
  2. Cahn P et al. AIDS 2022; 36(1): 39–48.
  3. DOVATO (dolutegravir/lamivudine) Summary of Product Characteristics (SmPC).
  4. Executive summary — UNAIDS. 2025 Global AIDS Update — AIDS, Crisis and the Power to Transform. Executive summary. Available at: https://www.unaids.org/en/resources/documents/2025/2025-global-aids-update-summary. Accessed October 2025.
  5. Fraysse J et al. Infect Dis Ther. 2025; 14(2): 357–383.
  6. Lazarus J et al. HIV Med. 2023; 24(Suppl. 2): 8–19.
  7. Figueroa M et al. Slides presented at HIV Glasgow. 10–13 November 2024. Glasgow, UK. O24.
  8. Cordova E et al. Lancet HIV 2025; 12(2): e95–e104.
  9. Rolle C et al. Open Forum Infect Dis 2023; 10(3): ofad101.
  10. Department of Health and Human Services (DHSS). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. September 2024.
  11. Gandhi R et al. JAMA 2025; 333(7): 609–628.
  12. ̌European AIDS Clinical Society (EACS) Guidelines. Version 12.1. November 2024.
  13. World Health Organization. Recommendations on first- and second-line antiretroviral regimens. July 2019.
  14. BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022 (2025 interim update). Accessed January 2026
  15. Trickey A et al. Lancet HIV 2023; 10(5): e295–e307.

PM-GB-DLL-WCNT-250004 | February 2026

Prescribing Information

Adverse event reporting

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK via the GSK Reporting Tool or on 0800 221441.